INTRODUCTION

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death in men and women worldwide.\(^1\) Recent identification of druggable mutations and development of inhibitors targeting the alterations has improved the treatment outcomes of lung cancers.\(^2-5\) However, in spite of the recent remarkable development of new treatment strategies, such as tyrosine kinase inhibitors and immunotherapies, patient survival has not markedly improved, suggesting the importance of discovering new genetic alterations and understanding their oncogenic roles on lung cancer.

In our previous study exploring the genome-wide profiles of chromosomal alterations in NSCLCs using microarray based comparative genomic hybridization (array-CGH) analysis, we observed that the 1q23.1 locus harboring the papillary renal cell carcinoma gene (PRCC) is recurrently amplified in non-small cell lung cancer (NSCLC). However, it is unknown whether PRCC is overexpressed in primary NSCLCs and whether PRCC overexpression contributes to lung tumorigenesis. In this study, we aimed to identify the profiles of PRCC expression in Korean NSCLC patients and to elucidate the role of PRCC overexpression on lung tumorigenesis.

Purpose: Papillary renal cell carcinoma (PRCC) gene, which located in 1q23.1, is recurrently amplified in non-small cell lung cancer (NSCLC). However, it is unknown whether PRCC is overexpressed in primary NSCLCs and whether PRCC overexpression contributes to lung tumorigenesis. In this study, we aimed to identify the profiles of PRCC expression in Korean NSCLC patients and to elucidate the role of PRCC overexpression on lung tumorigenesis.

Materials and Methods: We performed immunohistochemistry analysis with a tissue array containing 161 primary NSCLCs. Small interfering RNA targeting PRCC (siPRCC) was transfected into two lung cancer cell lines (NCI-H358 and A549), after which tumor growth, migration, and invasion were observed. Expressions of cell proliferation-, cell cycle-, and metastasis-related molecules were examined by Western blot analysis. We also explored the in vivo effect of PRCC silencing.

Results: PRCC overexpression was recurrently observed in NSCLCs (95/161, 59%). After siPRCC treatment, tumor cell proliferation, colony formation, and anchorage independent growth were significantly reduced (\(p<0.001\) for all three effects). Migration and invasiveness were also significantly repressed (\(p<0.001\) for both effects). Reflecting cell proliferation, cell cycle, and metastasis, the expressions of Ki67, cyclin D1, AKT-1, pAKT, NF-kB p65, vimentin and CXCL-12 were found to be downregulated. Through mouse xenograft analysis, we confirmed that PRCC silencing significantly repressed a xenograft tumor mass in vivo (\(p<0.001\)).

Conclusion: The present data provide evidence that PRCC overexpression is involved in the tumorigenesis and progression of lung cancer.

Key Words: Lung cancer, PRCC, overexpression, siRNA
cell carcinoma (PRCC) gene was recurrently amplified in NSCLC. Recent studies have shown that PRCC contains domains capable of transcriptional activation and that the fusion protein PRCC-TFE3 shows higher transcription activity than wild-type TFE3. However, besides the fusion partner of TFE3, the oncogenic function of PRCC is almost unknown, because PRCC is not homologous to any known protein. PRCC is also reported to contain three proline-rich (P-X-X-P) motifs that can potently participate in binding to Src homology 3 (SH3) domain-containing proteins. Proteins with a SH3 domain are known to play an important role in signaling pathways regulating the cytoskeleton, Ras protein, and Src kinase. In addition, PRCC contains several potential sites for kinase phosphorylation, suggesting that PRCC is involved in a signaling cascade that may contribute to tumorigenesis.

In support of this possibility, it was recently found that PRCC interacts with the cell cycle control protein Mad2B in renal cell carcinoma and translocates this protein to the nucleus where it exerts its mitotic checkpoint function. These data suggest that overexpression of PRCC may contribute to the tumorigenesis of solid tumors including lung cancer through a mechanism different from fusion with TFE3. However, there has been no report on whether PRCC is overexpressed in NSCLCs or on the biological role of PRCC overexpression in lung tumorigenesis.

In this study, we aimed to explore the expression of PRCC in primary NSCLCs and the biological roles of PRCC overexpression on the tumorigenesis and progression of lung cancers by blocking the expression of PRCC in the human lung cancer cell lines harboring PRCC overexpression.

MATERIALS AND METHODS

Lung cancer cell lines
Human lung cancer cell lines (NCI-H23, NCI-H358, NCI-H460, and A549) were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA) and maintained in DMEM and RPMI 1640 (Gibco BRL, Gaithersburg, MD, USA) supplemented with 10% FBS at 37°C under 5% CO2. As a control, CCD-25LU (a human normal pulmonary epithelial cell line) was purchased from ATCC and maintained in Eagle’s MEM supplemented with 10% FBS and 100 U/mL of penicillin/streptomycin.

Immunohistochemistry of NSCLC tissue microarray
We used a lung cancer tissue microarray (TMA) developed at Seoul St. Mary’s Hospital (Seoul, Korea) that contains 161 lung cancer tissues [81 adenocarcinomas (ACs) and 80 squamous cell carcinomas (SCCs)] under the approval of the Institutional Review Board of the Catholic University of Korea, College of Medicine (CUMC05U003). All cores from tumor tissue blocks were verified to contain tumor cells by histological examination. 4-μm sections of the TMA blocks were cut and used for immunohistochemistry (IHC) analysis. TMA sections were deparaffinized in xylene, hydrated with 100% ethanol and 95% ethanol, and rinsed in distilled water. Endogenous peroxidase was blocked with 0.1% H2O2. The section slides were then submitted to microwave antigen retrieval for pretreatment (10 mM citrate buffer, pH 6.0). The slides were incubated with serum blocking solution, primary antibody (anti-PRCC monoclonal antibody, clone D-3, 1:50, Santa Cruz Biotechnology, Santa Cruz, CA, USA), biotinylated secondary antibody, and streptavidin-horseradish peroxidase. Diaminobenzidine solution was used as a chromogen. The slides were counterstained in hematoxylin solution. The PRCC staining intensity was graded from 0 (no evidence of any nuclear immunoreactivity) to 3 (strongly positive immunoreactivity) by a board-certified pathologist. In this study, only the staining intensity of tumor cells was evaluated because the proportion of stained cells was constant throughout all cases. IHC grade 2 and grade 3 were deemed reflective of PRCC overexpression. Renal cell carcinoma and lung cancer tissues with known high expression of PRCC were used as a positive control for PRCC. The negative control used non-specific mouse IgG in place of the primary antibody.

Transfection of PRCC siRNAs
Three different PRCC-specific siRNAs (siPRCC-1, siPRCC-2, and siPRCC-3) were purchased from Invitrogen (Carlsbad, CA). Their sequences were as follows: siPRCC-1, UUG AUU UCU UCU CUC CCC GGG UUC GAG GAA AAG AAA UCA A; siPRCC-2, UGA CCA GGU GUU CUU CAG UUC CAG GCGU GGA ACU GAA GAA CAC CUG GUC A; siPRCC-3, AAG UCU UGG UCU UAG AAG AAC CCA GUC UAG ACG GCC UCU AAC ACC AAC AUU U. The siPRCC-1, -2, and -3 targeted exons 5, 7, and 3, respectively. To estimate the sequence-specific effectiveness of the PRCC-specific siRNAs, we also used a negative control siRNA (siNEG) (Invitrogen) that has no significant homology with any known sequences in the human genome. PRCC-specific siRNA was transfected into the cells at a final concentration of 100 nM using Lipofectamine RNAiMAX Transfection Reagent (Invitrogen) as described elsewhere. Cells were harvested at different time points for the following tests.

Western blot analysis
Transfected cells were harvested and lysed in cell lysis buffer (50 mM NaF, 150 mM NaCl, 10 mM sodium pyrophosphate, 2 mM EDTA, 0.1% Triton X-100) with protease inhibitor. Cell lysate was electrophoresed on 10% SDS-polyacrylamide gel and the gels were blotted onto a PVDF membrane (Millipore, Bedford, MA, USA). The membranes were blocked with 5% skim milk and then incubated overnight at 4°C with anti-PRCC and anti α-tubulin antibodies (Sigma, St. Louis, MO, USA). Mem-
branes were incubated with HRP-conjugated goat anti-rabbit IgG antibody (Sigma) for 1 hour at room temperature. Signals were visualized using an enhanced chemiluminescence system (Amersham-Pharmacia Biotech, Braunschweig, Germany). The expression of α-tubulin or β-actin was used as a control.

**Antibodies**

Antibodies for cyclin D1, AKT and phosphor-AKT were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies for NFκB, CXCR-12, and vimentin were obtained from Santa Cruz Biotechnology. Ki67 antibody was purchased from Abcam (Cambridge, UK). Anti-rabbit, anti-mouse, and anti-goat secondary antibodies conjugated to HRP, FITC, and TRITC were obtained from Santa Cruz Biotechnology.

**PRCC-specific real-time reverse transcription-PCR**

Total RNA was isolated from cells using TRIzol reagent (Invitrogen). Reverse transcription was performed using oligo-(dT) primer and SuperScript™ III reverse transcriptase (Invitrogen). Quantitative real-time reverse transcription-PCR (qRT-PCR) was performed with a ViiA™ 7 Real-Time PCR System using THUNDERBIRD™ SYBR® qPCR Mix (Toyobo, Osaka, Japan) and the following PRCC-specific primer set: 5′-ACACCTGGT CAGAGAACAAGCTCA-3′ (sense) and 5′-AGATCCTGGGAG CAATCAGTTCCA-3′ (antisense). GAPDH was used for normalization. Thermal cycling was performed as follows: one cycle at 95°C for 10 min, followed by 45 cycles of 95°C at 10 sec, 55°C for 30 sec and 72°C for 30 sec. Relative quantification was performed by the ΔΔCt method as described elsewhere.

**Cell proliferation assay**

Cells were seeded onto 96-well plates (2×10^4 cells per well) and transfected with siPRCCs. Cell growth was determined by the cell proliferation reagent WST-1 (Roche, Indianapolis, IN, USA) according to the manufacturer’s protocol. Optical density was read at 450 nm at various time points. Three independent experiments were done.

**Invasiveness and migration assay**

Invasiveness was assayed using the 24-well format transwell chambers (Becton Dickinson Labware, Franklin Lakes, NJ, USA) with 8 μm-pore size. siRNA transfected cells were added onto Matrigel (BD Biosciences, San Jose, CA, USA) coated filters in 200 μL of serum-free media (2×10^4 cells/filter). In the lower chambers, 500 μL of complete media containing 10% FBS was added. After 32-hour incubation at 37°C in the 5% CO₂ incubator, cells were stained with 0.5% crystal violet in 20% methanol and then examined under the microscope. Cells on the top surface of the membrane were removed by wiping with a cotton swab. The numbers of cells were counted in five microscopic fields at ×40 magnification. Migration assay was performed in the same manner but without the Matrigel coating on the filters. Six independent experiments were performed for each assay.

**Colonies formation assay**

Forty-eight hours after siRNA transfection, cells were seeded into six-well plates. About one week later, cells were washed with PBS and stained with 0.5% crystal violet. The colonies were manually counted. Six independent experiments were performed for each assay.

**Soft agar assay**

Forty-eight hours after siRNA transfection, 1000 cells were plated onto six-well plates in complete culture medium containing 0.35% low-melting-point (LMP) agarose on top of 0.6% LMP agarose in the same medium. After incubating for 2 weeks at 37°C in the 5% CO₂, colonies >0.1 mm in diameter were counted under a microscopic field at ×40 magnification. Six independent experiments were performed for each assay.

**Generation of enhanced green fluorescent protein stable expressing cell line**

To generate the stably expressing enhanced green fluorescent protein (EGFP), pEGFP-N1 plasmid (2.5 μg) was transfected using Lipofectamine™. Forty-eight hours after transfection, cells were selected by 0.8 μg/mL of G418 (Sigma) treatment. After 10 to 14 days selection, the remaining colonies were isolated and maintained with 0.4 μg/mL of G418. EGFP expression was confirmed by fluorescence microscope and flow cytometry.

**Mouse in vivo tumorigenesis model and intratumoral injection of siPRCC**

Six-week old female BALB/c athymic (nude) mice were purchased from Charles River Laboratories (Milan, Italy) and maintained under specific pathogen-free conditions. EGFP stable-expressed NCI-H358 cells (H358-pEGFP-N1) were injected subcutaneously at both flanks (2×10^5 cells/mouse). When the average volume of each tumor, which was established from the injected EGFP stable cells, reached 50 mm^3, siPRCC and siNEG were injected in 20 μL of PBS twice a week for 6 weeks. Tumor growth was monitored by measuring EGFP signals using the Maestro In Vivo Imaging System (Cambridge Research & Instrumentation, Inc., Woburn, MA, USA) with intra-peritoneal injection of ketamine/xylazine as the anesthetic drug combination. After 6 weeks, mice were sacrificed and tumor weights were measured. All animal experimental procedures were approved by The Catholic University of Korea Animal Ethics Committee (CUMS-2016-0251-03).

**Statistical analysis**

The statistical analysis was performed using the SPSS statistical software ver. 17 (SPSS Inc., Chicago, IL, USA). Statistical significance was determined by the two-tailed unpaired Student’s t-test for continuous variables. p values less than 0.050 were considered statistically significant.
RESULTS

Expression of PRCC in human primary lung cancer tissues
To examine the expression of PRCC in primary NSCLC, we screened PRCC protein expression level in 161 NSCLCs (81 ACs and 80 SCCs) by TMA-based IHC. Of 161 NSCLCs, 95 (59%) showed PRCC overexpression, ≥IHC grade 2 (Table 1). Tumor cells showed nuclear expression of PRCC (Fig. 1). Normal lung tissue did not show PRCC overexpression (data not shown). PRCC overexpression was significantly more common in SCC than AC (p=0.012). Other factors, such as age, sex, tumor size, lymph node metastasis, and tumor stage, did not show significant correlation with PRCC expression status (Table 1).

Repression of PRCC expression by siPRCC in lung cancer cell lines
Before PRCC knockdown, we examined baseline PRCC expression levels in four lung cancer cell lines (NCI-H23, NCI-H358, NCI-H460 and A549) by Western blot analysis. In three of the four cell lines, protein expression levels of PRCC were profoundly increased, compared with normal lung cells (CCD25-LU) (Fig. 2). Among them, NCI-H358 and A549 showed the highest levels of baseline PRCC expression (4.51 and 3.87 folds, respectively); therefore, both cells were selected for the following experiments. To assess the biological effects of PRCC overexpression on lung carcinogenesis, we transfected three PRCC-specific siRNA constructs (siPRCC-1, -2, and -3) and siNEG into the NCI-H358 and A549 cell lines. Of the three siPRCCs, siPRCC-1 showed best knockdown performance in

---

Table 1. Relationships among PRCC Expression and Clinicopathological Variables in 161 Non-Small Cell Lung Cancers

| Variable | n (%)       | Cases with PRCC overexpression (%) | p value |
|----------|-------------|-----------------------------------|---------|
| Total no.| 161         | 95 (59.0)                         |         |
| Tumor type |            |                                   |         |
| AC       | 81 (50.3)  | 40 (49.4)                         |         |
| SCC      | 80 (49.7)  | 55 (68.8)                         |         |
| Age (yr) |            |                                   |         |
| <65      | 63 (39.1)  | 41 (65.1)                         |         |
| ≥65      | 98 (60.9)  | 54 (55.1)                         |         |
| Sex      |            |                                   |         |
| Male     | 126 (78.3) | 78 (61.9)                         |         |
| Female   | 35 (21.7)  | 17 (48.6)                         |         |
| Tumor size |           |                                   |         |
| ≤3 cm    | 75 (47.2)  | 49 (65.3)                         |         |
| >3 cm    | 84 (52.8)  | 45 (53.6)                         |         |
| T factor |            |                                   |         |
| pT1, 2   | 133 (82.6) | 81 (60.9)                         |         |
| pT3, 4   | 28 (17.4)  | 14 (50.0)                         |         |
| N factor |            |                                   |         |
| pN0      | 103 (64.0) | 63 (61.2)                         |         |
| pN1+     | 58 (36.0)  | 32 (55.2)                         |         |
| Stage    |            |                                   |         |
| I        | 91 (56.5)  | 57 (62.6)                         |         |
| II       | 34 (21.1)  | 19 (55.9)                         |         |
| III      | 36 (22.4)  | 19 (52.8)                         |         |

AC, papillary renal cell carcinoma; SCC, squamous cell carcinoma.
both cell lines (Fig. 3). Therefore, all downstream functional analyses were performed using the siPRCC-1 (hereafter called siPRCC).

The effects of PRCC silencing on lung cancer cell growth
To explore the effects of PRCC on lung cancer cell growth, we performed proliferation and colony formation assays after PRCC knockdown. In the proliferation assay, both of the PRCC silenced cells showed significantly slower growth rates than that of the siNEG-transfected cells from 48 hours after siPRCC transfection (Fig. 4A). In the colony formation assay, the number of colonies from the siPRCC-treated cells was significantly lower than that from the siNEG-treated cells (NCI-H358: median 21.0, IQR 22.0–18.5 in siPRCC vs. median 77.0, IQR 83.0–72.5 in siNEG, p=1.902×10^{-6}; A549: median 16.0, IQR 17.5–15.3 in siPRCC vs. median 42.5 in siNEG, IQR 43.8–40.5, p=4.467×10^{-5}) (Fig. 4B). Next, we examined the PRCC-silencing effect on the anchorage independent growth of lung cancer cells by soft agar assay. The number of anchorage-independent colonies of the siPRCC-treated cells was significantly reduced, compared with that of the siNEG-treated cells (NCI-H358: median 10.0, IQR 11.8–7.5 in siPRCC vs. median 35.5, IQR 38.3–31.3 in siNEG, p=6.453×10^{-7}; A549: median 3.5, IQR 4.8–3.0 in siPRCC vs. median 11.5, IQR 12.0–11.0 in siNEG, p=2.794×10^{-5}) (Fig. 4C).

The effects of PRCC silencing on lung cancer cell migration and invasion
We next explored the effect of PRCC silencing on the capability of migration and invasiveness of the lung cancer cells. The number of migrating cells after PRCC knockdown was significantly lower than that in the siNEG-treated cells (NCI-H358: median 480.5, IQR 488.3–473.5 in siPRCC vs. median 1597.5, IQR 1618.8–1573.3 in siNEG, p=3.020×10^{-15}; A549: median 298.5, IQR 308.0–292.8 in siPRCC vs. median 1171.5, IQR 1186.3–1162.8 in siNEG, p=4.152×10^{-16}) (Fig. 5A). The number of invading cells was also significantly lower in PRCC knockdown than in the siNEG (NCI-H358: median 295.0, IQR 305.0–291.0 in siPRCC vs. median 641.0, IQR 645.5–626.0 in siNEG, p=4.532×10^{-13}; A549: median 174.0, IQR 182.5–164.8 in siPRCC vs. med-
dian 457.0, IQR 464.8–445.5 in siNEG, p=1.633×10^{-11} (Fig. 5B).

Mechanism of the anti-tumor effect after PRCC silencing
To explore the mechanism of tumor growth inhibition after PRCC silencing, we checked cell proliferation- and cell cycle-related markers, such as Ki67, cyclin D1, AKT-1, pAKT, and NF-kB p65 by Western blotting (Fig. 6). Expression levels of Ki67, AKT-1, and pAKT were profoundly decreased in both siPRCC-transfected cells, compared with siNEG-transfected cells. Expression levels of cyclin D1 and NF-kB p65 were also decreased after siPRCC treatment, but were observed in one of the two lung cancer cell lines: repressed cyclin D1 in NCI-H358 and repressed NF-kB p65 in A549. To explore the mechanism of repressed migration and invasion after PRCC silencing, we checked the expression of vimentin and CXCL-12 (Fig. 6). Expression of CXCL-12 was decreased in both siPRCC-transfected cells. Decreased expression of vimentin was observed in NCI-H358.

In vivo validation of anti-tumor effect after PRCC silencing
For visualization of in vivo growth of lung cancer cells, we constructed EGFP stable expressing NCI-H358 cells (H358-pEGFP-N1) (Fig. 7A). Then, the EGFP stable cells were injected into nude mice. To verify whether the growth suppression effect observed in in vitro PRCC silencing was consistently appeared in vivo, siPRCC was injected into the tumor mass for six weeks (twice a week), and we observed the tumor growth (Fig. 7B). After the initial intratumoral injection of siPRCC, the median fluorescence signal from the xenograft tumors was steadily reduced in time series observation up to 6 weeks (Fig. 7B and C). By contrast, the siNEG injected xenograft tumors showed steadily increased signals in time series observation. At 4 weeks after the injection, the fluorescence signals from the siPRCC-injected tumors became significantly lower than those from siNEG-injected tumors (p=3.837×10^{-5} at 6 weeks, n=6). When we collected the tumor mass after 6 weeks of initial injection, consistent with the growth kinetics, the weight of siPRCC-
DISCUSSION

Copy number alteration is a common genetic event in solid tumors including lung cancer, and they are known to contribute to tumorigenesis by affecting the activities of cancer-related genes in the altered chromosomal regions.\(^7\) Amalgamation of chromosome 1q has been reported to be recurrently occurred in NSCLCs. In our previous analysis of chromosomal alterations in NSCLC, the 1q21.1 locus was identified to be recurrently amplified.\(^8\) This situation led us to investigate the role of PRCC overexpression in lung tumorigenesis.

PRCC has been suggested as the fusion partner of TFE3 transcription factor, and the PRCC-TFE3 fusion protein showed higher TFE3 activity in renal cell carcinoma.\(^7\) However, PRCC-TFE3 fusion has not been reported in other solid tumors, suggesting that PRCC itself may have a different oncogenic mechanism in other solid tumors. Indeed, PRCC is known to contain proline rich motifs that can bind to SH3 domains.\(^7\) This interaction can play a role in regulating the cytoskeleton, Ras protein, and Src kinase pathway.\(^1\) This situation led us to investigate the role of PRCC in NSCLC. The aim of this study was threefold. First, we aimed to identify the profiles of PRCC expression in Korean NSCLC patients. Second, we aimed to elucidate the role of PRCC overexpression in lung tumorigenesis by knocking down overexpressed PRCC in two lung cancer cell lines that showed PRCC overexpression. Third, we attempted to confirm the in vitro effect of PRCC silencing observed in tissue culture condition by in vivo mouse model.

In IHC analysis of 161 Korean NSCLC cases, we found that 59% of the lung cancers involved PRCC overexpression. To our knowledge, this is the first evidence showing that overexpression of PRCC is a common occurrence in lung cancer. PRCC overexpression was significantly more common in SCCs than ACs; however, we could not observe significant correlations with other clinical features, such as tumor size, lymph node metastasis, or tumor stage, in this study. Considering that we analyzed a limited number of NSCLC cases in this study, further study will be required to confirm the clinical meaning of PRCC. The SCC dominance of PRCC overexpression observed in this study also needs further confirmation in a larger cohort. Although we could not make conclusive interpretation of PRCC overexpression on the clinical features of NSCLCs, PRCC

Fig. 5. Effects of PRCC knockdown on migration and invasion. (A) Motility potential of siPRCC- and siNEG-transfected cells was examined using transwell chambers. After crystal violet staining, the numbers of colonies in the five microscopic fields (×200) were counted. Bar chart in the right box represents the average number of migrated cells in siPRCC-treated cells and in siNEG-treated cells. (B) Invasive potential of siPRCC- and siNEG-transfected cells was examined using Matrigel-coated transwell chambers. After crystal violet staining, the numbers of colonies in the five microscopic fields (×200) were counted. Bar chart in the right box represents the average number of migrated cells in siPRCC-treated cells and in siNEG-treated cells. *p<0.001. PRCC, papillary renal cell carcinoma.

Fig. 6. Protein expressions of cell proliferation-, cell cycle-, and metastasis-related molecules in siPRCC- and siNEG-treated lung cancer cells. Expressions of Ki67, cyclin D1, AKT-1, pAKT, NF-κB p65, vimentin, and CXCL-12 were observed by Western blot analysis. β-actin was used as loading control.

injected xenograft tumor became lower than that with siNEG-injected tumor (ratio of weights, 3.45; 95% CI, 172.50±129.83 in siNEG vs. 50.00±27.39 in siPRCC; p=0.070, n=6).
overexpression in approximately 60% of the primary NSCLCs strongly suggests that PRCC overexpression can be useful as a tumor marker of NSCLC and may be involved in lung tumorigenesis.

In addition to the primary NSCLCs, three of the four lung cancer cell lines showed highly overexpressed PRCC, further supporting its oncogenic potential. After silencing the PRCC in two PRCC overexpressed lung cancer cell lines, cell growth rate, colony formation, anchorage independent growth, and invasive ness were repressed in both cells. Although we did not perform the induction of PRCC overexpression in PRCC non-overexpressed, normal lung epithelial cells to induce lung tumorigenesis, our data supports the role of PRCC overexpression in NSCLC tumorigenesis.

To determine the molecular mechanism of tumor growth inhibition after PRCC silencing, we assessed cell proliferation-related markers and compared the expression of molecules between siPRCC- and siNEG-treated cells. As expected, key molecules known to be involved in cell proliferation and cell cycle, such as Ki67, cyclin D1, AKT-1, pAKT, and NF-kB p65, were decreased in siPRCC-transfected cells, compared with siNEG-transfected cells, suggesting that overexpression of PRCC is involved in uncontrolled cell proliferation, which may contribute to lung tumorigenesis. In addition to the repressed cell proliferation, suppression of invasiveness was also observed after PRCC silencing in this study. To understand the molecular mechanism of repressed migration and invasion after PRCC silencing, we evaluated the expression of vimentin and CXCL-12. Vimentin is one of the key EMT markers that can induce tumor metastasis. Chemokines are known to play important roles in metastasis of cancer cells, and CXCL-12 is known to be involved in regulation of metastasis. Moreover, overexpression of CXCL-12 has been reported in various metastatic solid tumors, including lung cancer. In this study, expressions of related molecules were decreased after PRCC silencing, suggesting that overexpression of PRCC is involved in overexpression of vimentin and CXCL-12, which may contribute to enhancing the metastatic potential of lung cancer.

**Fig. 7.** siPRCC-mediated regression of established tumor growth *in vivo*. (A) Photograph of EGFP stable expressing NCI-H358 cells (H358-pEGFP-N1). (B) Whole-animal fluorescent signal images of H358-pEGFP-N1 tumor in nude mice. H358-pEGFP-N1 cells were transplanted into both flanks of immunodeficient nude mice. After 15 days, the mice were given intratumoral injections of siPRCC (left) or siNEG (right). Fluorescence is presented as a pseudocolor scale; red, the highest photon flux; blue, the lowest photon flux. (C) Monitoring of tumor growth by fluorescence. To investigate the tumor cell growth kinetics, injected H358-pEGFP-N1 cells were monitored for their GFP fluorescence. The total flux is expressed as the mean±SEM (n=6). (D) Monitoring of tumor growth by tumor weight. Tumor weights were measured at sacrifice and were compared between xenograft mice administered with PRCC siRNA and sterile PBS (n=6). *p<0.05, †p<0.001. PRCC, papillary renal cell carcinoma; EGFP, enhanced green fluorescent protein.
To trace the *in vivo* effects of PRCC silencing, we developed EGFP stable lung cancer cells and xenografted the cells into nude mice. When we injected siPRCC into the xenograft tumors, tumor growth was significantly reduced, compared with siNEG-injected tumors. Through this experiment, we confirmed the *in vivo* effect of PRCC silencing. All of the PRCC IHC data with primary NSCLC tissue array and *in vitro*/*in vivo* data suggest that PRCC overexpression can contribute to lung tumorigenesis. Additionally, repression of tumor growth after siPRCC injection into the mouse xenograft tumor also suggests the possibility that PRCC can be a therapeutic target.

There are several limitations to this study. First, although we observed recurrent PRCC overexpression in the primary NSCLCs and growth/migration inhibition after silencing overexpression *in vitro*, we could not observe significant clinical associations other than squamous cell carcinoma dominance in our primary NSCLCs. This may be due to the limitation of NSCLC cases in the NSCLC tissue array used in this study. Further larger scale analyses will be required to attain conclusive insights into the clinical implications of PRCC overexpression. Second, we did not evaluate whether artificial induction of PRCC overexpression can induce lung tumorigenesis in PRCC non-overexpressed normal lung epithelial cells.

In conclusion, we observed that PRCC overexpression is a common event in NSCLCs. When silenced PRCC expression in PRCC overexpressed cells, tumor growth was significantly reduced *in vitro* and *in vivo*. These data suggest that PRCC overexpression is involved in tumorigenesis and progression of lung cancer. This study provides a better understanding of lung tumorigenesis and suggests PRCC as a potential biomarker and therapeutic target of lung cancer.

**ACKNOWLEDGEMENTS**

This work was supported by a grant from the National Research Foundation of Korea (2017R1E1A1A01074913 and NRF-2017 M3C9A6047615).

**AUTHOR CONTRIBUTIONS**

Conceptualization: Yeun-Jun Chung. Data curation: Yeun-Jun Chung, Seung-Hyun Jung and Chan Kwon Jung. Formal analysis: Sun-Hee Jang and Yuzhu Jiang. Funding acquisition: Yeun-Jun Chung. Investigation: Sun-Hee Jang, Sun Shin, Seung-Hyun Jung and Yeun-Jun Chung. Methodology: Sun-Hee Jang, Yuzhu Jiang and Sun Shin. Project administration: Yeun-Jun Chung. Resources: Yeun-Jun Chung and Chan Kwon Jung. Software: Seung-Hyun Jung. Supervision: Yeun-Jun Chung. Validation: Sun-Hee Jang, Chan Kwon Jung and Yeun-Jun Chung. Visualization: Sun-Hee Jang and Sun Shin. Writing—original draft: Sun-Hee Jang and Yeun-Jun Chung. Writing—review & editing: Sun-Hee Jang, Chan Kwon Jung and Yeun-Jun Chung.

**ORCID iDs**

Sun-Hee Jang https://orcid.org/0000-0003-3016-7218
Seung-Hyun Jung https://orcid.org/0000-0003-1128-892X
Chan Kwon Jung https://orcid.org/0000-0001-6843-3708
Yeun-Jun Chung https://orcid.org/0000-0002-6943-5948

**REFERENCES**

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
2. Califorti S, Lococo F, Froesh P, Zappa F, André D. Target therapy in lung cancer. Adv Exp Med Biol 2016;893:127–36.
3. VanderLaan PA, Rangachari D, Mockus SM, Spotlow V, Reddi HV, Malcolm J, et al. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes. Lung Cancer 2017;106:17–21.
4. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–57.
5. Ke EE, Wu YL. EGFR as a pharmacological target in EGFR-mutant non-small–cell lung cancer: where do we stand now? Trends Pharmacol Sci 2016;37:887–903.
6. Kim TM, Yim SH, Lee JS, Kwon MS, Ryu JW, Kang HM, et al. Genotype–whole genome screening of genomic alterations and their clinicopathologic implications in non-small cell lung cancers. Clin Cancer Res 2005;11:8235–42.
7. Siddhar SK, Clark J, Gill S, Hamoudi R, Crew AJ, Gwilliam R, et al. The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet 1996;5:1333–8.
8. Weterman MA, Wilbrink M, Geurts van Kessel A. Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X:1) (p11.2;q21)-positive papillary renal cell carcinomas. Proc Natl Acad Sci U S A 1996;93:15294–8.
9. Pérot C, Boccon-Gibod L, Bouvier R, Daz F, Fournet JC, Fréneaux P, et al. Five new cases of juvenile renal cell carcinoma with translocations involving Xp11.2: a cytogenetic and morphologic study. Cancer Genet Cytofgenet 2003;143:93–9.
10. Weterman MA, Wilbrink M, Eleved M, Merkx G, van Groningen JJ, van Rooijen M, et al. Genomic structure, chromosomal localization, and embryonic expression of the mouse homolog of PRCC, a gene associated with papillary renal cell carcinoma. Cytofgenet Cell Genet 2001;92:326–32.
11. Mayer BI. SH3 domains: complexity in moderation. J Cell Sci 2001;114(Pr7):1253–63.
12. Weterman MA, van Groningen JJ, TeroTolen L, van Kessel AG. Impairment of MAD2B–PRCC interaction in mitotic checkpoint defective t(X;1)–positive renal cell carcinomas. Proc Natl Acad Sci U S A 2001;98:13088–13093.
13. van den Hurk WH, Martens GJ, Geurts van Kessel A, van Groningen JJ. Isolation and characterization of the Xenopus laevis orthologs of the human papillary renal cell carcinoma-associated genes PRCC and MAD2L2 (MAD2B). Cytofgenet Genome Res 2004;106:68–73.
14. Liu J, Kim SY, Shin S, Jung SH, Yim SH, Lee JY, et al. Overexpression of TFF3 is involved in prostate carcinogenesis via blocking mitochondria-mediated apoptosis. Exp Mol Med 2018;50:110.
15. Jiang Y, Yim SH, Xu HD, Jung SH, Yang SY, Hu HJ, et al. A potential oncogenic role of the commonly observed E2F5 overexpression in hepatocellular carcinoma. World J Gastroenterol 2011;17:470–7.
16. Xu H, Choe C, Shin SH, Park SW, Kim HS, Jung SH, et al. Silencing of KIF14 interferes with cell cycle progression and cytokinesis by blocking the p27(Kip1) ubiquitination pathway in hepatocellular carcinoma.
carcinoma. Exp Mol Med 2014;46:e97.
17. Vissers LE, Veltman JA, van Kessel AG, Brunner HG. Identification of disease genes by whole genome CGH arrays. Hum Mol Genet 2005;14 Spec No. 2:R215-23.
18. Kim TM, Yim SH, Shin SH, Xu HD, Jung YC, Park CK, et al. Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int J Cancer 2008;123:2808-15.
19. Tai AL, Yan WS, Fang Y, Xie D, Sham JS, Guan XY. Recurrent chromosomal imbalances in nonsmall cell lung carcinoma: the association between 1q amplification and tumor recurrence. Cancer 2004;100:1918-27.
20. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 2011;68:3033-46.
21. Guo F, Wang Y, Liu J, Mok SC, Xue F, Zhang W. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene 2016;35:816-26.